DiNicolantonio, J.J., Bhutani, J., McCarty, M.F., et al
Research indicates (Dong et al., 2024) that YSHSG treatment significantly reduces 24-h proteinuria in non-dialysis CKD patients while promoting the growth of beneficial gut microbiota (e.g., Faecalibacterium, Spirillaceae, Fusobacterium, Sutterella ) and suppressing potentially pathogenic bacterial species
The duration of results can vary, but many patients experience ongoing benefits with continued use under medical supervision
Size 100 l Form Liquid Description Boster Bio Anti-GPX1/Glutathione Peroxidase 1 Rabbit Monoclonal Antibody catalog # M01019-1
They are not one-size-fits-all solutions, and the best starting point depends on the person's goals, health history, medications, and clinician guidance
2022;36(7):e22399